SCHEMBL3487573

SCHEMBL3487573

CCc1ccc(Oc2ccc(N)c(CNC(=O)O)c2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40
LMNA P02545 2/20 0.39
GCK P35557 1/20 0.38
OPRM1 P35372 2/20 0.38
MAPT P10636 2/20 0.38
OPRD1 P41143 1/20 0.38
OPRK1 P41145 1/20 0.38
OPRL1 P41146 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
P2RY14 Q15391 1/20 0.38
CHRM2 P08172 1/20 0.38
CHRM4 P08173 1/20 0.38
ADRA2A P08913 1/20 0.38
CHRM1 P11229 1/20 0.38
ADRB3 P13945 1/20 0.38
ADRA2B P18089 1/20 0.38
S1PR1 P21453 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3487570 0.89 MMP13 (0.42) MAPK14SMN1; SMN2KDM4EHPGDALDH1A1
SCHEMBL3488176 0.88 TEAD4 (0.46) MAPK14SMN1; SMN2GCKMAPTFFAR4
SCHEMBL3488380 0.86 RAF1 (0.44) SMN1; SMN2MAPTKDM4EALDH1A1
SCHEMBL3488332 0.84 GCK (0.46) MAPK14SMN1; SMN2GCKCARM1PRMT6
SCHEMBL3488403 0.84 SMN1; SMN2 (0.42) SMN1; SMN2LMNAMAPTHTR2AHPGD
SCHEMBL30026819 0.83 SMN1; SMN2 (0.49) SMN1; SMN2RAB9ANPC1MAPTFFAR4
SCHEMBL3487214 0.82 ALDH1A1 (0.54) SMN1; SMN2LMNAMAPTALDH1A1GAA
SCHEMBL3487614 0.81 SMN1; SMN2 (0.52) SMN1; SMN2KDM4EHPGDALDH1A1
SCHEMBL3487706 0.81 PPARG (0.41) GCKCHRM4HTR2AFFAR4CARM1
SCHEMBL3487565 0.81 HTR2A (0.46) GCKCHRM4HTR2ACARM1PRMT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2138484-B1 FUSED BICYCLIC HETEROARYL DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2015-08-26 EP disclosed
US-20100048564-A1 FUSED BICYCLIC HETEROARYL DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2010-02-25 US disclosed
EP-2138484-A1 FUSED BICYCLIC HETEROARYL DERIVATIVES Daiichi Sankyo Company, Limited (JP) 2009-12-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048564-A1 FUSED BICYCLIC HETEROARYL DERIVATIVE PPARG, GPR119, PPARA MAPK14 1880/4885SMN1; SMN2 4397/4885RAB9A 1582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.